PCDHB16

Across TCGA pan-cancer cohorts, PCDHB16 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PCDHB16 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher PCDHB16 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PCDHB16 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

STAD, BRCA, and UCEC are the cancer types where PCDHB16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	II,III,IV	0.312	0.693	.032	6	view →
BRCA	OS	Median	All	0.190	0.580	.008	6	view →
UCEC	DFS	Median	II,III,IV	0.880	0.709	.025	6	view →
LIHC	DFS	Median	II,III,IV	0.119	0.437	<.001	6	view →
KIRP	OS	Median	All	0.680	0.903	.038	3	view →
SKCM	DFS	Median	III,IV	0.813	0.565	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PCDHB16–STAD (DFS)

Open the STAD breakdown →